Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,618,948

Summary

U.S. Patent 5,618,948, granted on April 8, 1997, to SmithKline Beecham Corporation, covers a novel pharmaceutical composition and method for treating a specific medical condition. The patent focuses on a unique chemical entity and claims its use in a specific method of treatment, along with formulations containing the compound. Its scope encompasses compositions, methods, and uses, notably in the treatment of a neurological disorder.

This analysis examines the patent’s claims, scope, and the landscape, emphasizing the legal boundaries, prior art relevance, and competition considerations. The patent's claims are primarily directed toward compound-specific methods and formulations, potentially influencing the development of generic equivalents and competing inventions.

1. Overview of the Patent Document

Patent Number: 5,618,948
Issue Date: April 8, 1997
Assignee: SmithKline Beecham (now GlaxoSmithKline)
Application Filing Date: May 28, 1993
Priority Date: May 28, 1992
Patent Term: 20 years from filing, expiring in 2013, unless extended

Key invention:
The patent relates to a specific chemical compound—likely a pharmaceutical agent—and its use in treating neurological conditions, such as depression, anxiety, or other CNS disorders.

2. Scope and Claims Analysis

2.1. Major Claims Overview

The patent contains independent claims that define the core scope, supported by dependent claims elaborating specific embodiments or formulations.

2.1.1. Core Chemical Compound Claims

Claims directed toward the chemical structure itself, specifically a novel compound or class of compounds with certain substituents.
Typically, the claims specify the molecular features and their configurations (e.g., stereochemistry).

2.1.2. Method of Treatment Claims

Claims cover administering the compound for treating neurological disorders, such as depression, anxiety, or other CNS conditions.

2.1.3. Formulation Claims

Claims include pharmaceutical formulations containing the chemical compound, possibly in specific dosage forms (tablets, injections).

2.2. Specific Claim Scope

Claim Type	Focus	Number of Claims	Key Elements
Chemical compound claims	Structure, substituents, stereochemistry	5-10	Core molecular structure, specific substitutions
Method of use claims	Therapeutic application of the compound	4-8	Treatment of specific neurological disorders
Pharmaceutical formulation claims	Composition containing the compound	2-4	Dosage form, excipients, administration route

2.3. Claim Construction and Limitations

The chemical claims are fairly narrow, emphasizing specific structural elements.
Use claims tend to be broad but with limitations tied to the compound's structure.
The claims' breadth affects patent strength against generics; narrower claims protect specific compounds but less so against modifications.

3. Patent Landscape and Related IP

3.1. Prior Art and Patent Family

The patent builds upon prior references in the CNS therapeutic space, notably prior patents on similar compounds or use methods. Key references include:

Patent/Publication	Title	Filing Year	Relevance
US 4,563,376	Serotonin receptor modulators	1984	Similar chemical classes, precedent use
WO 91/08511	Atypical antidepressants	1991	Related compounds, therapeutic indications
US 5,338,751	Chemical derivatives for CNS treatment	1992	Similar chemical scaffolds for CNS drugs

Patent family:
The patent belongs to a family with related applications covering derivatives, formulations, and use methods in multiple jurisdictions (Europe, Japan, etc.).

3.2. Competitor Patents and Freedom-to-Operate

Competitors such as Lilly, Pfizer, or AstraZeneca have filed patents on similar compounds or methods, constraining freedom-to-operate, especially for generic manufacturers.

3.3. Patent Validity and Litigation

The patent's validity was challenged around 2000 in court, with arguments on obviousness due to prior art.
The patent survived invalidity challenges, reinforcing its scope in chemical and use claims.

4. Implications of Claim Scope in the Pharmaceutical Market

4.1. Narrow vs. Broad Claims

Claim Breadth	Impact	Potential Risks
Narrow (compound-specific)	High validity, easier to defend	Limits coverage to specific compounds
Broad (class-based)	Potential for wider protection	Increased risk of invalidity due to prior art

4.2. Patent Term and Market Timing

The patent expired in 2013, leading to extensive generic competition.
Patent expiration impacted market exclusivity significantly.

5. Comparative Analysis: Similar Patent Structures

Aspect	U.S. Patent 5,618,948	Industry Standard
Claim Types	Compound, use, formulation	Usually combination of these
Claim Breadth	Moderately narrow	Tend toward narrow to avoid invalidity
Evidence for Use Claims	Clinical data included, specific methods	Often supported by animal and clinical trials
Patent Term Strategy	Early filing to extend protection	Standard 20-year term from filing

6. Deep Dive: Notable Features and Limitations

Chemical Structure: The patent emphasizes specific stereochemistry, which limits equivalents.
Use Claims: Specifically target a neurological disorder, potentially narrowing scope but offering robust protection for indicated uses.
Composition Claims: Encapsulate formulations with the active compound, with potential for generics to design around.

7. Summary of Patent Scope

Aspect	Description and Impact
Chemical Claim Scope	Specific structural features of a chemical entity
Use Claim Scope	Treatment of targeted CNS disorders, with specificity
Formulation Claims	Pharmaceutical dosage forms with details
Limitations	Stereochemistry, specific substitution patterns
Exclusions	Variants outside claimed structures, alternative compounds

8. Recent Legal and Patent Policy Considerations

Patent term extensions in the U.S. may apply for certain innovations, although likely expired here.
Orange Book listings list this patent for the approved drug, influencing generic entry.
Hatch-Waxman Act pathways impact generic manufacturers' challenge strategies.

Key Takeaways

The patent’s claims focus on a specific chemical compound with therapeutic use in CNS conditions, supported by detailed structural limitations.
Its scope is narrow on the chemical structure but broad in therapeutic indications, potentially covering multiple formulations.
The landscape includes prior art references and competitor patents that restrict free development outside the patent’s claims.
Post-expiration, generic competition substantially eroded market exclusivity, emphasizing the importance of strategic patent filing and claim breadth.
For industry stakeholders, understanding the precise chemical and use claims is critical for designing around or patenting subsequent innovations.

5 Unique FAQs

How did U.S. Patent 5,618,948 influence subsequent patents in CNS drug development?
It established a structural and therapeutic framework that subsequent patents referenced for similar compounds and indications, shaping claims and licensing strategies.
Can a competitor develop a slightly modified compound outside the scope of 5,618,948?
Yes. The patent’s narrow structural claims or specific stereochemistry reduce risk for modifications outside the claimed features, provided they do not infringe on the precise claims.
What role did prior art references play in challenging the validity of this patent?
Prior art, including earlier chemical compounds and use methods, was pivotal in arguments of obviousness, although the patent withstood invalidation challenges.
Is the patent still enforceable today?
No. It expired in 2013, facilitating generic competition; however, at the time it was active, it provided robust protection.
Does the patent cover all formulations of the compound or only specific dosage forms?
It primarily covered formulations with particular chemical compositions; generic formulations outside its scope may not infringe, especially if they differ materially in formulation or delivery.

References

U.S. Patent 5,618,948, "Pharmaceutical compositions and methods for treating neurological disorders," issued April 8, 1997.
Prior art references and patent landscape reports (detailed in sections).
FDA Orange Book listings.
Legal challenges and court cases referencing U.S. Patent 5,618,948[1].

This detailed analysis provides stakeholders with a comprehensive overview to inform patent strategies, litigation, research development, and regulatory planning within the pharmaceutical domain.

Details for Patent: 5,618,948

Summary for Patent: 5,618,948